WO2022112806A3 - Food supplement or medicinal or pharmaceutical composition inhibiting virus infection, advantageously infection of sars-cov-2 and ibv coronaviruses and formulation thereof - Google Patents

Food supplement or medicinal or pharmaceutical composition inhibiting virus infection, advantageously infection of sars-cov-2 and ibv coronaviruses and formulation thereof Download PDF

Info

Publication number
WO2022112806A3
WO2022112806A3 PCT/HU2021/000014 HU2021000014W WO2022112806A3 WO 2022112806 A3 WO2022112806 A3 WO 2022112806A3 HU 2021000014 W HU2021000014 W HU 2021000014W WO 2022112806 A3 WO2022112806 A3 WO 2022112806A3
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
infection
ibv
coronaviruses
cov
Prior art date
Application number
PCT/HU2021/000014
Other languages
French (fr)
Other versions
WO2022112806A2 (en
Inventor
László GYULAI
Éva SÁRDI
Zsolt István NÉMETH
Original Assignee
Gyulai Laszlo
Sardi Eva
Nemeth Zsolt Istvan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gyulai Laszlo, Sardi Eva, Nemeth Zsolt Istvan filed Critical Gyulai Laszlo
Priority to EP21890365.6A priority Critical patent/EP4210505A2/en
Publication of WO2022112806A2 publication Critical patent/WO2022112806A2/en
Publication of WO2022112806A3 publication Critical patent/WO2022112806A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is for use in the control of COVID- 19 coronavirus infection, which became worldwide in 2020. The present invention relates to the methylation of a metabolite, macromolecule, protein, RNA, DNA involved in a multicomponent food supplement with easily mobilizable methyl groups for the control of viral infection, preferably SARS-COV-2 and IBV coronaviruses, a pharmaceutical or pharmaceutical composition comprising at least one methyl donor and at least one methyl acceptor in such a way that that the ratio of methyl donors to methyl acceptors is in accordance with the preferred molar ratios. Definitions : Methyl donor compounds : Organic compounds methylated on N-, S- and 0 heteroatoms where methyl groups thereof transfer into transmethylation cycle after oxidative demethylation. Methyl acceptor compounds : Organic compounds for use in binding methyl (hydroxy methyl ) groups. The invention also relates to a formulation method and a method of administration for use in preparing the compositions.
PCT/HU2021/000014 2020-09-11 2021-11-10 Food supplement or medicinal or pharmaceutical composition inhibiting virus infection, advantageously infection of sars-cov-2 and ibv coronaviruses and formulation thereof WO2022112806A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21890365.6A EP4210505A2 (en) 2020-09-11 2021-11-10 Food supplement or medicinal or pharmaceutical composition inhibiting virus infection, advantageously infection of sars-cov-2 and ibv coronaviruses and formulation thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP-2000298 2020-09-11
HU2000298A HUP2000298A1 (en) 2020-09-11 2020-09-11 Food supplement or medicinal or pharmaceutical composition to control viral infection, particularly sars-cov-2 and ibv coronaviruses and their formulation

Publications (2)

Publication Number Publication Date
WO2022112806A2 WO2022112806A2 (en) 2022-06-02
WO2022112806A3 true WO2022112806A3 (en) 2022-09-01

Family

ID=89993188

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2021/000014 WO2022112806A2 (en) 2020-09-11 2021-11-10 Food supplement or medicinal or pharmaceutical composition inhibiting virus infection, advantageously infection of sars-cov-2 and ibv coronaviruses and formulation thereof

Country Status (3)

Country Link
EP (1) EP4210505A2 (en)
HU (1) HUP2000298A1 (en)
WO (1) WO2022112806A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1124548A2 (en) * 1998-10-30 2001-08-22 MERCK PATENT GmbH Compositions for the treatment and prevention of cardiovascular diseases
EP2283835A2 (en) * 2002-06-19 2011-02-16 N.V. Nutricia Method and preparation for treating metabolic stress
US20200054660A1 (en) * 2016-12-09 2020-02-20 St. Jude Children's Research Hospital Dna methylation profiling for t-cell immunotherapy
WO2021202245A1 (en) * 2020-04-02 2021-10-07 Egaceutical Corporation Viral treatment regimens

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1124548A2 (en) * 1998-10-30 2001-08-22 MERCK PATENT GmbH Compositions for the treatment and prevention of cardiovascular diseases
EP2283835A2 (en) * 2002-06-19 2011-02-16 N.V. Nutricia Method and preparation for treating metabolic stress
US20200054660A1 (en) * 2016-12-09 2020-02-20 St. Jude Children's Research Hospital Dna methylation profiling for t-cell immunotherapy
WO2021202245A1 (en) * 2020-04-02 2021-10-07 Egaceutical Corporation Viral treatment regimens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MCCADDON ANDREW ET AL: "COVID-19: A methyl-group assault?", MEDICAL HYPOTHESES, vol. 149, 1 April 2021 (2021-04-01), US, pages 110543, XP055942678, ISSN: 0306-9877, DOI: 10.1016/j.mehy.2021.110543 *

Also Published As

Publication number Publication date
HUP2000298A1 (en) 2022-03-28
WO2022112806A2 (en) 2022-06-02
EP4210505A2 (en) 2023-07-19

Similar Documents

Publication Publication Date Title
Wiesner et al. Fosmidomycin for the treatment of malaria
BR0213522B8 (en) hydroxypyrimidinone derivative compounds, pharmaceutical composition, and use of a compound
NO20100302L (en) Compositions containing organic compounds
MXPA03002022A (en) Multivalent neuraminidase inhibitor conjugates.
WO2001022791A8 (en) Controlled release compositions comprising nimesulide
FI3785730T3 (en) Aluminium compounds for use in therapeutics and vaccines
BR9907832A (en) Composition of sulfite-containing propofol
BRPI0408085A (en) composition and method for the treatment and prevention of bacterial enteric infections
RS50972B (en) Pharmaceutical composition containing gestagens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate
AP1776A (en) Reconstitutable parenteral composition containing a cox-2 inhibitor.
UA102187C2 (en) Diindolylmethane-containing pharmaceutical composition for oral administration
WO2022112806A3 (en) Food supplement or medicinal or pharmaceutical composition inhibiting virus infection, advantageously infection of sars-cov-2 and ibv coronaviruses and formulation thereof
PT1175489E (en) OLIGONUCLEOTIDES CONTAINING AN ANTISENSE SEQUENCE STABILIZED BY A SECONDARY STRUCTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
BR9912142A (en) Substituted 6-benzyl-4-oxypyrimidines, process for their preparation and compositions containing them
BR9908458A (en) 11beta-benzaldoxim-estra-4,9-dienocarbonic acid thiolesters replaced by s, processes for their preparation and pharmaceutical preparations containing these compounds
BRPI0507326A (en) solid retarded formulation for parenteral administration
BRPI0614197B8 (en) pharmaceutically effective composition in a dosage form for peroral administration containing at least one of the active ingredients indomethacin and acemetacin, forms of administration, and use of the composition
WO2007124700A3 (en) Pharmaceutical composition containing taxane derivative destined for the preparation of an infusion solution, method of preparation thereof and use thereof
BR112022019198A2 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF EPIDEMIC RIBONUCLEIC ACID VIRUS INFECTIONS, AND, USE OF A THERAPEUTICLY EFFECTIVE AMOUNT OF PIRONARIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ARTEMISININ OR A DERIVATIVE THEREOF
WO2013066208A3 (en) Pharmaceutical composition based on epigallocatechin gallate-containing nano-micelles and use thereof
AU1039400A (en) Opioid analgesic
HUP0004701A2 (en) New salts of desloratadine, pharmaceutical compositions containing them and process for the preparation thereof
WO2022090807A3 (en) Cannabigerol and tetrahydrocannabivarin antidote formulations and methods of using the same
EE05007B1 (en) 9a-N- (N'-arylcarbamoyl) - and 9a-N- (N'-arylthiocarbamoyl) -9-deoxo-9a-aza-9a-homoerum thromycin Ahalogen derivatives, process for their preparation, pharmaceutical composition and use
EE200200599A (en) Cyclostostin Compound for use as an antidiabetic drug, pharmaceutical preparation containing it, preparation of the compound and preparation and microorganism necessary for this

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 202337026542

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021890365

Country of ref document: EP

Effective date: 20230411

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21890365

Country of ref document: EP

Kind code of ref document: A2